Testing is underway on vaccines to intercept brewing colon cancer before it takes root

Key Points:

• Dr. Stacy Norton, who has Lynch syndrome, participated in early clinical trials of a vaccine aimed at preventing colon cancer by training the immune system to target precancerous growths caused by the genetic mutation.
• Lynch syndrome is an inherited condition affecting about 1 million Americans, significantly increasing the risk of colorectal and other cancers due to faulty DNA repair genes, with carriers advised to have frequent colonoscopies.
• At least three vaccines targeting Lynch syndrome-related precancers are in development, including trials in the U.S. and Britain, with promising early results showing reduced precancerous polyps and activation of tumor-fighting immune cells.
• The vaccine approach differs from traditional cancer prevention vaccines by focusing on abnormal proteins produced by Lynch syndrome tumors rather than viral infections, potentially offering a new way to prevent gene-caused cancers.
• Rising colorectal cancer rates in younger adults may be linked to increased Lynch syndrome diagnosis through expanded genetic testing, highlighting the importance of early detection and prevention strategies for high-risk individuals.